Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
89Zr-olaratumab in PDGFR Alpha Positive Solid Tumours and Soft Tissue Sarcoma
NCT06537596Phase 1Recruiting
- Sponsor
- Telix Pharmaceuticals Limited
- Start
- Oct 2024
- Primary completion
- Oct 2027
- Modality
- Antibody Conjugates, Monoclonal Antibodies, Peptide-Drug Conjugates
- Countries
- 1
01
Overview
Phase 1, open-label trial of TLX300-CDx in soft tissue sarcoma (STS) and solid tumor (3 arms), sponsored by Telix Pharmaceuticals Limited. Primary endpoints: Clinical safety and tolerability of 89Zr-TLX300-CDx at 30 days, Biodistribution of 89Zr-TLX300-CDx at 6 days and 2 more. Started Oct 2024; status: recruiting.
02
Drugs
TLX300-CDx
03
Conditions
soft tissue sarcoma (STS)solid tumor
Beyond the preview
Go deeper on NCT06537596.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06537596.